Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59

Abstract Whilst COVID vaccines proved to be effective in preventing severe COVID disease, they failed to control the emergence of variant viruses and antibody responses waned quickly. We report the findings of a recombinant β-SARS-CoV-2 variant virus-like particle (VLP) vaccine composed of the viral...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Linda Earnest, Daniel Fernandez Ruiz, Melissa A. Edeling, Julio Carrera Montoya, Ashley Huey Yiing Yap, Chinn Yi Wong, Lauren E. Holz, Stephanie Gras, Simon Collett, James P. Cooney, Kathryn C. Davidson, Samantha L. Grimley, Damian F. J. Purcell, Jason Roberts, Jamie Mumford, Chee Wah Tan, Lin-Fa Wang, Dale I. Godfrey, Matthew Frieman, Dhiraj Hans, Elizabeth Vincan, Danielle E. Anderson, Kanta Subbarao, Marc Pellegrini, Jason M. Mackenzie, Steven Rockman, William R. Heath, Joseph Torresi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2026-01-01
coleção:	npj Vaccines
Acesso em linha:	https://doi.org/10.1038/s41541-025-01355-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!